TARS Q4 2022 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M+2858.6% YoY

Gross Profit

$10M96.0% margin

Operating Income

-$15M-150.6% margin

Net Income

-$14M-136.0% margin

EPS (Diluted)

$-0.53

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$228M

Total Liabilities

$35M

Stockholders' Equity

$193M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$338,000	+2858.6%
Gross Profit	$10M	$362,000	+2551.9%
Operating Income	-$15M	-$14M	-4.2%
Net Income	-$14M	-$15M	+8.4%

Revenue Segments

License and Service

$10M100%